Background
==========

Human herpesvirus 8 (HHV8) or Kaposi sarcoma herpesvirus (KSHV) is the probable causative agent of two distinct lymphoproliferative disorders: primary effusion lymphoma (PEL) and the plasma cell variant of multicentric Castleman disease (MCD) in addition to Kaposi sarcoma (KS) \[[@B1]\].

Primary effusion lymphoma (PEL), or alternatively: body cavity lymphoma is a non-Hodgkin\'s lymphoma (NHL) of B-cell origin that develops predominantly in the serous body cavities \[[@B2]\]. The lymphoma cells, although lacking many conventional B-cell markers, carry immunoglobulin gene rearrangement and express syndecans, suggesting pre-plasma cell origin. At the clinico-pathological level, PEL is characterized by liquid growth in the serous body cavities associated with spreading along the serous membranes without infiltrative or destructive growth patterns \[[@B3],[@B4]\]. Morphologically, PEL bridges immunoblastic and anaplastic features and frequently displays a certain degree of plasmacell differentiation. In all known cases, the monoclonal B-cell population is infected with HHV-8. Half of the lymphomas are dually infected with HHV-8 and Epstein-Barr virus (EBV) \[[@B5]\]. In the context of AIDS, most cases are associated with other KSHV/HHV8-related diseases such as Kaposi\'s sarcoma (KS) or multicentric Castleman\'s disease (MCD). As PEL typically lacks a solid component, its diagnosis rests on the cytological examination of body fluid. Phenotypically, expression of the CD45 antigen (\> 90% of cases) confirms the lymphoid derivation of PEL cells, which exhibit an indeterminate immunophenotype, as they usually lack expression of B- and T-cell associated antigens (the majority of cases reported). There are, however, cases in the literature that had a B-cell or T-cell phenotype respectively \[[@B1]\].

Conversely, PEL cells generally express various markers associated with activation, including CD30 (approximately 75% of cases), CD38, CD71 and the epithelial membrane antigen. Moreover, PEL cells express several plasma cell markers including CD138, VS38c and MUM-1/IRF4 \[[@B1]\].

The prognosis of PEL is poor, as the median survival in the previously published series does not exceed 3 months \[[@B3],[@B6]-[@B10]\].

Given its rarity, however, there are very few longitudinal observational series of patients with PEL and no large prospective trials have ever defined optimal treatment strategies \[[@B11]\].

Prior to the introduction of antiretroviral therapy, the therapeutic results were unsatisfactory in cohorts of HIV+ patients, despite the use of aggressive polychemotherapy regimens including anthracyclines. The significant improvement in the prognosis of AIDS-related lymphomas observed in the antiretroviral therapy era also applies to the PEL setting.

In addition, the routine use of growth factors, such as the granulocyte colony-stimulating factor (G-CSF), to avoid prolonged periods of neutropenia resulting from chemotherapy is standard practice for all AIDS-related lymphoma (ARL) patients.

Despite the improvement in therapeutical strategies during the last few years, there is no evidence of a cure for PEL patients with conventional systemic chemotherapy addressed to aggressive NHL. The suggested benefit of high-dose Methotrexate in association with CHOP (Cyclophosphamide, Doxorubicin, Prednisolone and Vincristine)-like regimens is negatively balanced by the hampered toxicity of Methotrexate in the presence of serous effusions \[[@B1]\].

Novel approaches for body cavity lymphoma therapy outside traditional chemotherapy have been suggested as well \[[@B11]\]. These include the addition of antiviral therapy as well as inhibition of specific cellular targets. Anti-tumor activity of the antiviral therapy directed against KSHV/HHV8 infection has been reported. This experience is based on single case reports. Patients with a diagnosis of PEL, related or not to HIV infection, experienced prolonged complete remission after the intracavitary administration of Cidofovir - an antiviral agent. Intracavitary Cidofovir, as well as interferon-α, may represent a reasonable choice in patients\' refractory to conventional chemotherapy, or in elderly patients not eligible for more toxic systemic therapies \[[@B12]\].

Another approach may be to target NF-κB through the use of proteasome inhibition with drugs, such as Bortezomib that induces apoptosis of PEL cell lines *in vitro*\[[@B13]\].

In the present study we have investigated 11 different primary effusion (body cavity based) lymphoma-derived cell lines to compare the drug sensitivity pattern, in order to find new potentially successful chemotherapy agents, that are not used in current treatment protocols.

Methods
=======

Cell lines and culture conditions
---------------------------------

The following primary effusion (body cavity based) lymphoma-derived cell lines were used in the present study. CRO-AP/2, CRO-AP/5, CRO-AP/6, BC-2, BC-3 were established from pleural effusion, CRO-AP/3, HBL-6, BC-3, BCBL-1, JSC-1 were established from ascites fluid and BCP-1 from peripheral blood.

Body-cavity cell lines were cultured in IMDM (Sigma), supplemented with 20% heat-inactivated (at 56°C for 45 min) fetal calf serum (FCS, Sigma), 100 IU/ml penicillin (Sigma), 100 μg/ml streptomycin (Sigma) and 2 mM L-glutamine (Sigma). Cell lines were grown at 37°C in the presence of 5% CO~2~. Cultures were fed twice weekly with the above-mentioned medium; maintained at ca. 0.5 × 10^6^cells/ml. All cell lines were examined daily in their culture vessels under an inverted microscope. Absence of mycoplasma contamination was routinely assessed using staining with Hoechst 33258.

*In vitro*drug sensitivity assay
--------------------------------

*In vitro*drug resistance of body-cavity cell lines were assessed using a 3-day cell culture on microtiter plates. 27 drugs (Table [1](#T1){ref-type="table"}) were tested, each at 4 different concentrations in triplicates on 384 well plates. Each well was loaded with 30 μl cell suspension containing 9000 cells. After three days of incubation the living and dead cells were differentially stained using fluorescent VitalDye (Biomarker Hungary). The precise number of living and dead cells was determined using a custom built-automated laser confocal fluorescent microscope (a modified Perkin-Elmer UltraView LCI) at the Karolinska Institute core Visualization Facility (KIVIF). The images were captured using the computer program QuantCapture 4.0 \[[@B14],[@B15]\]. Image correction and counting of living and dead cells was carried out by the program QuantCount 5.0. All programs were created by the authors, using the symbol based graphical programming environment OpenLab Automaton (Improvision). The 15 control wells, that were used to determine the control cell survival (CCS), contained cells with only culture medium and 50 nl DMSO without drugs. 5 wells contained cells with culture medium alone. Comparing the two types of control wells no toxic effect of DMSO could be seen. Mean cell survival (MCS) was determined from the average of cell survival of all 11 body-cavity cell lines (Table [2](#T2){ref-type="table"}).

###### 

Chemotherapic agents used in the present study

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                           Clinical\       Half time   *In vivo*\    *In vitro*used\   *In vitro*\       Ref          QAUC
                                                                           dose                        AUC^72\ hr^   concentrations    AUC^72\ hr^                    
  ---------------------------------- ------------------- ----------------- --------------- ----------- ------------- ----------------- ----------------- ------------ ---------------
  Antimetabolites                    Folic acid          Methotrexate      12 g/m^2^       24          623,70        0,033 - 4,17      12,000-1499,976   \[[@B21]\]   0,019 - 2,405

                                                                                                                                                                      

                                     Purine              Cladribine        5 mg/m^2^       3           5,67          0,007 - 0,83      0,480-59,976      \[[@B22]\]   0,085-10,578

                                                                                                                                                                      

                                                         Fludarabine       25 mg/m^2^      2           27,72         0,167 - 20,83     12,000-1499,976   \[[@B23]\]   0,433-54,112

                                                                                                                                                                      

                                                         6-Mercaptopurin   85 mg/m^2^      4           138,60        0,556 - 69,44     39,997-4999,680   \[[@B24]\]   0,289-36,073

                                                                                                                                                                      

                                     Pyrimidine          Cytarabine        1 g/m^2^        2           221,76        0,133 - 16,66     9,596-1199,520    \[[@B25]\]   0,043-5,409

                                                                                                                                                                      

                                                         Fluorouracil      400 mg/m^2^     0.25        69,30         0,333 - 41,66     23,996-2999,520   \[[@B26]\]   0,346-43,283

                                                                                                                                                                      

                                                         Gemcitabine       1000 mg/m^2^    0.7         388,08        0,267 - 33,33     19,198-2399,760   \[[@B27]\]   0,049-6,184

                                                                                                                                                                      

  Alkylating/alkylating-like         Nitrogen mustards   Chlorambucil      0.2 mg/m^2^     2           33,60         0,667 - 83,33     47,998-5999,760   \[[@B28]\]   1,429-178,564

                                                                                                                                                                      

                                     Platinum            Carboplatin       360 mg/m^2^     3           665,28        0,007 - 0,83      0,480-59,976      \[[@B29]\]   0,001-0,090

                                                                                                                                                                      

                                                         Oxaliplatin       130 mg/m^2^     5.74        270,46        0,033 - 4,17      2,400-299,952     \[[@B30]\]   0,009-1,109

                                                                                                                                                                      

  Spindle poison/mitotic inhibitor   Taxane              Docetaxel         85 mg/m^2^      0.6         24,95         0,067 - 8,33      4,798-599,760     \[[@B31]\]   0,192-24,040

                                                                                                                                                                      

                                                         Paclitaxel        175 mg/m^2^     3           257,80        0,013 - 1,67      0,956-119,520     \[[@B27]\]   0,004-0,464

                                                                                                                                                                      

                                     Vinca               Vinblastin        1.7 mg/m^2^     0.83        1,71          0,00067 - 0,083   0,048-5,998       \[[@B32]\]   0,028-3,510

                                                                                                                                                                      

                                                         Vincristine       1.32 mg/m^2^    2           1,55          0,00067 - 0,083   0,480-59,976      \[[@B33]\]   0,309-38,636

                                                                                                                                                                      

                                                         Vinorelbine       80 mg/m^2^      40          498,96        0,007 - 0,83      4,798-599,760     \[[@B34]\]   0,010-1,202

                                                                                                                                                                      

  Cytotoxic/antitumor antibiotics    Anthracyclin        Daunorubicin      1.5 mg/kg       18          531,56        0,033 - 4,17      2,400-299,952     \[[@B35]\]   0,005-0,564

                                                                                                                                                                      

                                                         Doxorubicin       50 mg/m^2^      30          1091,48       0,013 - 1,66      0,956-119,520     \[[@B36]\]   0,001-0,110

                                                                                                                                                                      

                                                         Epirubicin        90 mg/m^2^      15          604,21        0,013 - 1,66      0,960-119,952     \[[@B27]\]   0,002-0,199

                                                                                                                                                                      

                                     Streptomyces        Dactinomycin      1.5 mg/m^2^     36          8,98          0,003 - 0,42      0,240-29,995      \[[@B37]\]   0,027-3,340

                                                                                                                                                                      

                                                         Bleomycin         8 IU/kg/day     6           33,26         0,008 - 1         0,576-72,000      \[[@B38]\]   0,017-2,165

                                                                                                                                                                      

                                                         Mitomycin         20 mg/m^2^      1           4,44          0,003 - 0,33      0,317-39,600      \[[@B39]\]   0,071-8,929

                                                                                                                                                                      

                                                         Hydroxyurea       15 mg/m^2^      2           630,00        0,333 - 41,66     23,996-2999,520   \[[@B40]\]   0,038-4,761

                                                                                                                                                                      

  Topo-isomerase in-hibitors         Camptotheca         Topotecan         1.2 mg/m^2^     3           2,49          0,007 - 0,83      0,054-6,718       \[[@B41]\]   0,022-2,693

                                                                                                                                                                      

                                                         Etoposide         100 mg/m^2^     4           221,76        0,133 - 16,66     9,596-1199,520    \[[@B25]\]   0,043-5,409

                                                                                                                                                                      

                                                                                                                                                                      

  Other                                                  Asparaginase      30000 IU/m^2^   8           26,56         0,033 - 4,17      2,400-299,952     \[[@B42]\]   0,090-11,294

                                                                                                                                                                      

                                                         Bortezomib        1.45 mg/m^2^    40          21,62         0,007 - 0,83      0,480-59,976      \[[@B43]\]   0,022-2,774

                                                                                                                                                                      

                                                         Prednisolone      1 mg/kg/day     3           41.58         0,16666 - 20,83   11,998-1499,760   \[[@B44]\]   0,289-36,069
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

The average Mean Cell Survival (MCS) of the eleven body cavity lymphoma cell lines at different drug concentrations, expressed as the Q Area Under Curve values (QAUC).

                                           125 × dilution        25 × dilution   5 × dilution   1 × dilution              125 × dilution   25 × dilution   5 × dilution   1 × dilution
  --------------------- ------------------ --------------------- --------------- -------------- -------------- ---------- ---------------- --------------- -------------- --------------
  Effective drugs       **Chlorambucil**   **Epirubicin**                                                                                                                 
                        **MCS**            14.8560               46.6236         80.8708        84.7608        **MCS**    19.2643          37.3816         63.5034        85.1459
                        **SD**             15.3967               12.9966         21.0326        22.0111        **SD**     14.6115          16.3379         19.2617        26.7694
                        **QAUC**           1,4285                7,1426          35,7129        178,5643       **QAUC**   0,0016           0,0079          0,0397         0,1985
                        **Paclitaxel**     **Dactinomycin**                                                                                                               
                        **MCS**            17.0131               45.1537         67.7781        89.5709        **MCS**    7.9351           36.0115         67.0155        86.7944
                        **SD**             24.0155               49.5533         35.9258        22.0081        **SD**     8.4436           31.4395         26.8592        24.4412
                        **QAUC**           0,0037                0,0185          0,0927         0,4636         **QAUC**   0,0267           0,1336          0,6679         3,3397
                        **Daunorubicin**   **Docetaxel**                                                                                                                  
                        **MCS**            20.7690               27.3619         63.7950        87.2387        **MCS**    19.7376          21.9731         37.6060        59.5325
                        **SD**             25.0224               24.1810         31.5421        23.0699        **SD**     21.0333          20.3415         21.1706        27.0225
                        **QAUC**           0,0045                0,0226          0,1129         0,5643         **QAUC**   0,1923           0,9616          4,8081         24,0404
                        **Vinorelbine**    **Vinblastin**                                                                                                                 
                        **MCS**            18.1346               20.5045         40.0830        53.0230        **MCS**    26.8433          40.9968         67.9391        81.0989
                        **SD**             16.8776               21.5082         22.6266        26.5102        **SD**     32.9835          31.9132         33.5183        17.2183
                        **QAUC**           0,0096                0,0481          0,2404         1,2020         **QAUC**   0,0281           0,1404          0,7020         3,5100
                        **Asparaginase**   **Fluorouracil**                                                                                                               
                        **MCS**            33.4151               62.3275         90.6113        94.4347        **MCS**    41.1156          58.9125         70.3122        83.0342
                        **SD**             25.9953               34.9567         26.1363        23.3606        **SD**     19.1314          27.2339         23.4010        19.8986
                        **QAUC**           0,0903                0,4517          2,2587         11,2937        **QAUC**   0,3463           1,7313          8,6566         43,2831
                        **Etoposide**      **Doxorubicin**                                                                                                                
                        **MCS**            30.6138               50.2125         64.2707        74.6943        **MCS**    29.0927          66.8651         77.2076        80.7702
                        **SD**             20.8709               23.8410         23.6330        19.0535        **SD**     19.1960          25.0111         26.0959        27.3229
                        **QAUC**           0,0433                0,2164          1,0818         5,4091         **QAUC**   0,0009           0,0044          0,0219         0,1095
                        **Gemcitabin**     **Methotrexate**                                                                                                               
                        **MCS**            31.4369               45.9785         58.4073        67.9991        **MCS**    47.1542          44.9205         70.0761        84.2659
                        **SD**             33.0357               38.5124         37.0529        36.6568        **SD**     22.4628          21.6895         25.4751        25.4385
                        **QAUC**           0,0495                0,2473          1,2367         6,1837         **QAUC**   0,0192           0,0962          0,4810         2,4050
                        **Vincristine**    **Topotecan**                                                                                                                  
                        **MCS**            43.8400               69.1932         80.2086        81.6665        **MCS**    41.8048          75.3319         84.1050        90.7907
                        **SD**             34.7208               35.8971         29.9816        32.6203        **SD**     16.4675          24.5366         25.2812        25.3696
                        **QAUC**           0,3091                1,5455          7,7273         38,6364        **QAUC**   0,0215           0,1077          0,5385         2,6926
                                                                                                                                                                          
  Non-effective drugs   **Bortezomib**     **Bleomycin**                                                                                                                  
                        **MCS**            79.4105               66.8656         68.2865        64.8357        **MCS**    60.3729          69.3422         76.5090        80.8431
                        **SD**             25.4732               25.6668         28.0206        24.9547        **SD**     16.7323          18.8710         22.7197        16.8950
                        **QAUC**           0,0222                0,1110          0,5548         2,7739         **QAUC**   0,0173           0,0866          0,4330         2,1650
                        **Cladribine**     **6-mercaptopurin**                                                                                                            
                        **MCS**            81.0033               82.0998         84.1061        92.0852        **MCS**    74.0197          87.8677         97.1334        98.2332
                        **SD**             21.2666               22.0174         20.1630        21.3224        **SD**     28.3769          23.3376         30.0858        25.3860
                        **QAUC**           0,0846                0,4231          2,1156         10,5778        **QAUC**   0,2886           1,4429          7,2146         36,0729
                        **Oxaliplatin**    **Cytarabine**                                                                                                                 
                        **MCS**            87.0156               89.3148         82.6868        86.8853        **MCS**    69.9787          77.2199         83.5057        89.0542
                        **SD**             30.3307               26.7413         24.1939        25.6311        **SD**     31.2151          36.2648         38.6377        32.5155
                        **QAUC**           0,0089                0,0444          0,2218         1,1090         **QAUC**   0,0433           0,2164          1,0818         5,4091
                        **Prednisolone**   **Mitomycin**                                                                                                                  
                        **MCS**            98.9838               99.8113         95.6985        92.9011        **MCS**    73.4043          79.2375         80.0565        79.4133
                        **SD**             12.7979               15.5728         14.2013        14.0330        **SD**     28.5533          19.7620         18.7334        19.3133
                        **QAUC**           0,2886                1,4428          7,2139         36,0693        **QAUC**   0,0714           0,3571          1,7857         8,9286
                        **Hydroxyurea**    **Carboplatin**                                                                                                                
                        **MCS**            88.8788               86.3322         97.5959        98.8578        **MCS**    113.3868         103.2988        113.4341       110.1786
                        **SD**             21.5473               19.8568         17.5610        18.7218        **SD**     39.2983          27.4344         43.5238        38.6427
                        **QAUC**           0,0381                0,1904          0,9522         4,7611         **QAUC**   0,0007           0,0036          0,0180         0,0902
                        **Fludarabine**                                                                                                                                   
                        **MCS**            67.0129               76.1851         79.2040        95.8649                                                                   
                        **SD**             43.0343               35.3340         37.6906        19.6811                                                                   
                        **QAUC**           0,4329                2,1645          10,8223        54,1117                                                                   

Drugs
-----

For the *in vitro*drug sensitivity test 27 drugs were used (summarized in Table [1](#T1){ref-type="table"}). All the drugs were dissolved in 50% dimethyl sulfoxide (DMSO) - 50% phosphate buffered saline (PBS) and were printed on the 384 well plates using high-density array replicator metal pins with 50 nl replica volumes in a Biomek 2000 fluid dispenser robot (Beckman). The same robot was used to generate the drug masterplates containing the triplicates of four different drug dilutions (1 ×, 5 ×, 25 ×, 125 ×) using a single tip automatic pipettor dispenser head. The starting concentration of the dilution series for the individual drugs was initially determined based on the solubility of the different agents.

The drug plates that were used in this study were also tested on a large number of *in vitro*tumor cell lines and cells from primary tumor samples. In these assays we could show that it was possible to find sensitive cell lines for each individual drug, demonstrating that all the drugs on the plate were active \[[@B16],[@B17]\] (data not shown).

To calculate the relationship between the *in vitro*drug concentrations and the *in vivo*ones, we used **area under curve**(AUC; area under the plasma, concentration curve versus time) values of the individual drugs. For this comparison Quotient of Area Under Curve values (QAUC^72\ hr^) were determined by the following formula:

$$\left. in\quad vitro\textsf{~used~concentration} \times \textsf{72~hours(}\mu\textsf{g} \times \textsf{hr}\slash\textsf{ml)}\slash in\quad vivo\textsf{~AU}\textsf{C}^{\textsf{72hr}}\left( \mu\textsf{g} \times \textsf{h}\slash\textsf{ml} \right) \right.$$

The *in vivo*AUC^72\ hr^corresponds to the area under curve value achieved in patients under a 72 hours period. The *in vivo*AUC^72\ hr^was established from the clinical dose and half-time using the standard trapezoidal rule calculation. The *in vivo*AUC^72\ hr^data is summarized in the seventh column of Table [1](#T1){ref-type="table"}. The detailed references to the clinical dose and to the *in vivo*halftime data are available at the Swedish pharmacological website <http://fass.se>. A QAUC^72\ hr^value higher than 1 indicates that the *in vitro*drug concentration is higher than the one used in the clinical practice. If this value is 1, it means that the *in vitro*concentration corresponds to the clinically achieved *in vivo*concentration.

Results
=======

The *in vitro*drug sensitivity assay
------------------------------------

We have tested the drug sensitivity patterns of the body cavity lymphoma lines in short term, *in vitro*survival assays. The clinical origin and viral status of the individual lines is summarized in Figure [1](#F1){ref-type="fig"}. Each cell line was tested against 27 different drugs, in triplicates, at four different concentrations. The assay was carried out on 384 well plates. After 3 days of incubation each individual well of the test plates was photographed using a custom developed, automated extended field confocal microscope. Living and dead cells were differentially stained using viability dependent fluorescent dyes as shown in Figure [2](#F2){ref-type="fig"}. Each individual living or dead cell was identified counted and their fluorescence intensity distribution was recorded using automated image analytic and quantitation programs. For each well the percentage of surviving cells was calculated by comparing the number of living cells in the given well to the average of living cells in the untreated control wells.

![**Heat map representation of the hierarchical clustering of the simplified drug sensitivity data of the individual cell lines against all the drugs along with the presence of EBV in the cell lines, the HIV status and the age of the patients and the anatomical location of the founder sample (A - ascites, P - pleural effusion, B - blood)**. Intensity of the color shows the scale of the sensitivity. Black is resistant, brightness of the red color is proportional to the effectiveness of the drug.](1471-2407-11-441-1){#F1}

![***In vitro*drug resistance of body cavity cell lines was assessed using a 3 day survival assay on microtiter plates on single cell level**. The top panel shows the 384 well plates, the colored area shows the drugs, each at 4 different concentrations in triplicates. The highest concentrations are on the left and each adjacent column represents a 5-fold serial dilution. The middle panel is the magnification of a mosaic of microscopic images of six wells treated with the dilution series of one drug. The living and dead cells were differentially stained using fluorescent dyes as shown in yellow and blue colors on the digitally colored images. The bottom panel shows a close-up of a single microscopic field within one well.](1471-2407-11-441-2){#F2}

The summarized drug sensitivity pattern of the body cavity lymphoma cell lines
------------------------------------------------------------------------------

The summarized cell survival data is shown in Figure [3](#F3){ref-type="fig"}. The middle line of the individual curves represents the Mean Cell Survival (MCS) for all the cell lines along with the ± Standard Deviations of the means (SD - gray shaded area) for the four different dilutions of the 27 drugs. Drugs were considered to be more universally active if they showed less standard deviation around the means.

![**Mean values and standard deviations of drug sensitivity of eleven body cavity cell lines for 27 different cytostatic drugs; x axis: increasing concentrations of the drug, y axis: fraction of surviving cells 0-100%**. The drug was considered to be effective if the survival was below 50% at least at one concentration. Non-effective drugs: survival is above 50% even at the highest concentration.](1471-2407-11-441-3){#F3}

Most of the lines were sensitive for sixteen of the 27 drugs where sensitivity was defined as less than 50% mean survival at any of the drug dilutions (effective drugs). If more than half of the cells were alive even at the highest concentration than the drug was considered to be ineffective.

We found that the sixteen effective drugs against body-cavity lymphoma were the following in the order of effectiveness: Dactinomycin, Chlorambucil, Paclitaxel, Vinorelbine, Epirubicin, Docetaxel, Daunorubicin, Vinblastin, Doxorubicin, Etoposide, Gemcitabine, Asparaginase, Fluorouracil, Topotecan, Vincristine and Methotrexate.

Most body-cavity lymphoma lines were resistant to Oxaliplatin, Bleomycin, 6-Mercaptopurine, Hydroxyurea, Cladribine, Carboplatin, Bortezomib, Cytosine-arabinosid, Prednisolone, Mitomycin and Fludarabin. Although the Oxaliplatin, Cisplatin and Prednisolone drugs were not effective against any of the body-cavity lymphoma lines these drugs show concentration-dependent growth-inhibitory effect on other cell lines or primary tumors in parallel experiments (data not shown) at the same concentration as used in this paper \[[@B18]\].

Heat map of the cluster analysis
--------------------------------

In order to identify possible co-segregation of the sensitivity patterns of the individual drugs as well as to systematically compare all the lines with each other, we have carried out unsupervised two-dimensional hierarchical clustering of the simplified drug sensitivity data using the Cluster 3.0 program for MacOS X. The results were visualized using the program TreeView \[[@B19]\]. The sensitivity to the drug was represented on a 5 step scale where every step represents less than 50% viability at the four different drug dilutions. (Resistant - if more than 50% survival at the highest concentration, maximum sensitivity - if less than 50% survival at the lowest concentration.) The graphical representation of the clustering results, along with the EBV, HIV status and the presence of concomitant Kaposi sarcoma, are shown in Figure [1](#F1){ref-type="fig"}.

Pharmacokinetic comparison
--------------------------

Absolute drug sensitivity values have relatively little clinical relevance if they are not correlated with clinically achievable *in vivo*concentrations. In order to analyze the data in relation to the pharmacokinetic behavior of the given drugs we have plotted the mean survival values as the function of the Quotient of the Area Under Curve (QAUC^72\ hr^) values of the particular drugs. The QAUC^72\ hr^values of a drug were created by dividing the calculated *in vitro*AUC^72\ hr^values by the *in vivo*achievable AUC values (which were calculated from clinical dose and half-time). As shown in Figure [4](#F4){ref-type="fig"}. most drugs were tested in the pharmacologically most relevant range of QAUC^72\ hr^(close to 1).

![**Drug sensivity mean values of the survival of the body cavity lymphoma lines, plotted against QAUC^72\ hrs^values identify Epirubicin, Daunorubicin, Vinorelbine and Paclitaxel as novel candidate drugs against body cavity lymphomas**.](1471-2407-11-441-4){#F4}

Plotting the mean cell survival for each individual drug against a common QAUC^72\ hr^axis shows that Daunorubicin, Epirubicin, Paclitaxel and Vinorelbine were the most effective drugs (low survival at low QAUC^72\ hr^values). Moreover most body cavity lymphoma lines were sensitive to these drugs. Importantly, Doxorubicin, the only antracyclin drug that is currently included in chemotherapy protocols against body cavity lymphomas showed a rather heterogeneous effect. Two of the eleven lines were highly sensitive for Doxorubicin whereas two were completely resistant at the maximum drug concentration that we could reach in the current assay (QAUC = 0.11). The two lines (JSC-1 and BC-3) were, in general, the least sensitive for chemotherapeutic drugs, however were still sensitive for Daunorubicin, Epirubicin and Vinorelbine.

Dactinomycin showed the highest killing efficiency in the present *in vitro*assay. The calculation of the QAUC^72\ hr^value for the corresponding Dactinomycin concentration however revealed that the concentration that was required for the high killing effect is higher than the levels that are realistically achievable in a patient.

When treating the body-cavity lymphoma cells with Carboplatin at low QAUC^72\ hr^values, a relative increase in the number of surviving cells was observed as compared to non-treated controls. The survival was above 100% in case of all the 11 lines suggesting that low dose Carboplatin protected from spontaneous cell death.

Discussion
==========

*In vitro*growing cell lines are the closest model systems available today for studying the biological features of body cavity lymphomas. The cell lines that were used in the present study represent a variety of different origin. The investigation included cell lines established from ascites fluid, pleural effusion or from the peripheral blood of PEL patients. Despite their different origin, the body-cavity lymphoma lines showed a remarkably similar sensitivity pattern for a number of drugs. Only one cell line was highly resistant for most of the drugs (JSC1) whereas two cell lines (BC1 and BCBL-1) showed increased overall sensitivity to most of the drugs.

The presented data suggests that, for a number of cytostatic drugs the body cavity lymphoma cell lines share a common cytotoxic drug sensitivity profile. These profiles show no obvious correlation with the biological or clinical features of the lymphomas. Clustering of the drug sensitivity data revealed that the profiles are independent of the EBV status, anatomical localization of the lesion, the age the patient or the rapidity of the progression of the disease. The two cell lines (BCP-1 and BC-3) that arouse from HIV negative patients showed relatively low drug sensitivity.

The current treatment alternative is a combination of Methotrexate with CHOP (Cyclophosphamide, Doxorubicin, Prednisolone, Vincristine)-regimes. The present data showed that the cell lines exhibit varying sensitivity to Methotrexate and Vincristine and are completely resistant to Prednisolone.

Cyclophosphamide or Ifosphamide were not tested on the body cavity lymphoma lines, because both of these compounds are prodrugs that have to be converted into active metabolites by the liver *in vivo*.

It has been reported that the proteasome inhibitor Bortezomib induces apoptosis of the cell lines BCBL-1 and BCP-1 *in vitro*\[[@B13]\]. In this study only BCBL-1 showed detectable sensitivity to Bortezomib and only at the highest concentration whereas all the other lines were resistant.

In the present study body cavity lymphoma lines showed considerable sensitivity for anti-microtubule drugs and anthracyclins. Importantly all lines were sensitive to Epirubicin and Vinorelbine even at low QAUC^72\ hr^values. Epirubicin required tenfold lower concentration than the *in vivo*achievable concentration to kill more than 80% of the cells for most of the lines. Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer and lymphomas, but has not yet been tested against body cavity lymphomas \[[@B20]\].

In summary, the analysis of drug sensitivity profiles of the available body cavity lymphoma lines against 27 commonly used drugs revealed considerable heterogeneity in drug response. Four drugs, namely, Daunorubicin, Epirubicin, Paclitaxel and Vinorelbine showed uniformly high efficiency on the cell lines. These drugs are not yet included in the current chemotherapy protocols of body cavity lymphomas. The heterogeneity of drug response also suggests that optimal care of the lymphoma patients would include the determination of drug sensitivity patterns of the primary tumor samples and that these patients would benefit from assay guided individualized therapy.

Conclusions
===========

We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay guided individualized therapy might be required to optimize therapeutic response.
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